Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Stathmin domain-containing protein 1 (STMND1) is a small, evolutionarily ancient protein classified within the stathmin family. It features an N-terminal motif that is both myristoylated and palmitoylated, targeting it to cell membranes, and a stathmin-like domain (SLD) with tubulin-binding properties as well as a nuclear localization signal. STMND1 is highly expressed in multiciliated epithelial cells, where it localizes to motile cilia, plasma membranes, and nuclei. Its subcellular localization is regulated by its interaction with soluble tubulin; tubulin binding inhibits nuclear translocation of STMND1, suggesting a role as a sensor of cytoplasmic tubulin concentration. Overexpression of STMND1 increases ciliary length but may result in nuclear morphology defects. STMND1 can associate with nuclear spliceosomal proteins, pointing to a possible role in pre-mRNA processing. Despite its conserved features and cilium-related functions, STMND1 is not yet linked to specific diseases or recognized as a therapeutic pharmacological target
Not applicable (no drugs known to target STMND1)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Stathmin domain-containing protein 1 (STMND1).